COVID-19 Among Patients With Inflammatory Rheumatic Diseases

Esatoğlu, Sinem Nihal; Taşçılar, Koray; Babaoğlu, Hakan; Beş, Cemal; Yurttaş, Berna; Akar, Servet; Pehlivan, Özlem; Akleylek, Cansu; Tecer, Duygu; Seyahi, Emire; Yuce-Inel, Tuba; Alpay-Kanitez, Nilufer; Bodakçı, Erdal; Tekgöz, Emre; Çolak, Seda; Bolek, E. C.; Koca, Süleyman Serdar; Kalyoncu, Umut; İçaçan, Ozan Cemal; Uğurlu, Serdal; Oz, Hande Ece; Hamuryudan, Vedat; Hatemi, Gülen

doi:10.21203/rs.3.rs-115378/v1

Cited by 4 publications

(5 citation statements)

References 24 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies supported that patients who take biological and conventional DMARDs have less morbidity in the case of COVID-19 [2]. Moreover, in another study from Turkey consisting of 167 patients with inflammatory rheumatic disease, biologic and conventional DMARDs did not seem to cause worse outcomes [12]. However, overall, 18% of all the inflammatory arthritis patients discontinued bDMARDs in the first 100 days of the pandemic.…”

Section: Discussionmentioning

confidence: 94%

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Kalyoncu¹,

Pehlıvan²,

Akar³

et al. 2021

Turk J Med Sci

Self Cite

View full text Add to dashboard Cite

Background/aim To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.

show abstract

Section: Discussionmentioning

confidence: 94%

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Kalyoncu¹,

Pehlıvan²,

Akar³

et al. 2021

Turk J Med Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…Currently data confirming that COVID-19 severity in patients with IMIDs depends on well-known risk factors also described in the general population, including male sex, older age, and the presence of comorbidities, such as diabetes, obesity, renal, and pulmonary diseases. 7,10,11,28,30 During the pandemic, treatment with IM/IS in high-risk patients has been challenging to determine the best standard of care for SAR-CoV-2 infection. In general, IM/ IS seem not to affect COVID-19 course 7,30 ; however, if analyzed individually, some of them could have a beneficial effect, whereas others may be associated with ICU admission and death.…”

Section: Discussionmentioning

confidence: 99%

“…7,10,11,28,30 During the pandemic, treatment with IM/IS in high-risk patients has been challenging to determine the best standard of care for SAR-CoV-2 infection. In general, IM/ IS seem not to affect COVID-19 course 7,30 ; however, if analyzed individually, some of them could have a beneficial effect, whereas others may be associated with ICU admission and death. 10,11,28 Given the observational design of this registry, it has some important limitations.…”

Section: Discussionmentioning

confidence: 99%

Does the Use of Immunosuppressive Drugs Impact on SARS-CoV-2 Infection Outcome? Data From A National Cohort of Patients With Immune-Mediated Inflammatory Diseases (SAR-COVID Registry)

Isnardi¹,

Soriano

Graf³

et al. 2022

J Clin Rheumatol

View full text Add to dashboard Cite

Elea Phoenix had provided unrestricted grants. None of them has participated or influenced the development of the project, data collection, analysis, and interpretation, or the drafting of this report. They do not have access to the information collected in the database. Availability of data and material: All data and materials generated and analyzed during the current study belong to the SAR-COVID registry of the Argentine Society of Rheumatology. They are available from the corresponding author upon reasonable request. The authors declare that all relevant data are included in the article and its supplementary information files. More information about the registry is available at https:// www.unisar.reumatologia.org.ar/registros_sarcovid.php.

show abstract

“…In a cross-sectional study of 206 patients, 1 out of 77 patients on rituximab tested positive for COVID-19 immediately post-rituximab administration and had an uneventful course despite being elderly [15]. A recent multicenter study from Turkey concluded that biological treatment, including rituximab, does not seem to affect COVID-19 outcomes [16].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review

et al. 2021

View full text Add to dashboard Cite

A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by nasal swab polymerase chain reaction (PCR) while asymptomatic, 6 weeks earlier. He started with cough and shortness of breath 2 weeks after his initial positive test. After developing symptoms, he tested negative twice by nasal swab PCR, but the PCR of his bronchioloalveolar lavage was positive for SARS-CoV-2. He did not develop antibodies against coronavirus. Prednisone 15 mg daily was continued, and he received remdesivir, and convalescent plasma with quick recovery. We reviewed the literature to search for similar cases. Our case suggests that SARS-CoV-2 infection in patients on rituximab may have an atypical presentation and the diagnosis may be delayed due to negative PCR testing in the nasal swab. Patients may benefit from treatment with convalescent plasma.

show abstract

COVID-19 Among Patients With Inflammatory Rheumatic Diseases

Cited by 4 publications

References 24 publications

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Does the Use of Immunosuppressive Drugs Impact on SARS-CoV-2 Infection Outcome? Data From A National Cohort of Patients With Immune-Mediated Inflammatory Diseases (SAR-COVID Registry)

COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review

Contact Info

Product

Resources

About